Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Hagop M. Kantarjian, Elihu H. Estey, Susan O’Brien et al.|Cancer|2006Cited by 607
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Farhad Ravandi‐Kashani et al.|Cancer Discovery|2018Cited by 570
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian, Emil J. Freireich, Farhad Ravandi et al.|Blood|2010Cited by 399
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Marina Konopleva, Kathryn G. Roberts et al.|Blood|2016Cited by 385
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Joseph D. Khoury, Audrey L. Lamb et al.|Blood|2016Cited by 346